Atea Pharmaceuticals (AVIR) EBIT: 2019-2024
Historic EBIT for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$192.9 million.
- Atea Pharmaceuticals' EBIT fell 132.93% to -$39.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$130.7 million, marking a year-over-year decrease of 194.42%. This contributed to the annual value of -$192.9 million for FY2024, which is 17.54% down from last year.
- According to the latest figures from FY2024, Atea Pharmaceuticals' EBIT is -$192.9 million, which was down 17.54% from -$164.2 million recorded in FY2023.
- In the past 5 years, Atea Pharmaceuticals' EBIT ranged from a high of $138.4 million in FY2021 and a low of -$192.9 million during FY2024.
- For the 3-year period, Atea Pharmaceuticals' EBIT averaged around -$162.6 million, with its median value being -$164.2 million (2023).
- Its EBIT has fluctuated over the past 5 years, first spiked by 1,354.55% in 2021, then plummeted by 194.42% in 2022.
- Atea Pharmaceuticals' EBIT (Yearly) stood at -$11.0 million in 2020, then soared by 1,354.55% to $138.4 million in 2021, then crashed by 194.42% to -$130.7 million in 2022, then dropped by 25.65% to -$164.2 million in 2023, then decreased by 17.54% to -$192.9 million in 2024.